Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO)

CUSIP: 87975F104

Q4 2024 13F Holders as of 31 Dec 2024

Type / Class
Equity / Common Stock, no par value
Shares outstanding
34,382,284
Total 13F shares
3,563,053
Share change
+1,486,953
Total reported value
$14,680,234
Price per share
$4.12
Number of holders
37
Value change
+$6,102,927
Number of buys
29
Number of sells
3

Quarterly Holders Quick Answers

What is CUSIP 87975F104?
CUSIP 87975F104 identifies TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Bay Shore Trust
3/4/5
10%+ Owner
mixed-class rows
5,631,721
mixed-class rows
$20,414,715 21 Nov 2024
VANGUARD GROUP INC
13F
Company
3.3%
1,151,527
$7,392,804 30 Sep 2024
13F
Christopher Chapman MD
3/4/5
CEO & Chairman, Director
class O/S missing
975,610
$6,048,782 08 Feb 2024
Craig Eagle
3/4/5
Director
class O/S missing
487,805
$3,024,391 08 Feb 2024
BlackRock, Inc.
13F
Company
1.1%
366,878
$2,355,356 30 Sep 2024
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.69%
238,737
$1,533,329 30 Sep 2024
13F
Nathen Fuentes
3/4/5
Chief Financial Officer
class O/S missing
101,134
$627,031 08 Feb 2024
Bank of New York Mellon Corp
13F
Company
0.15%
51,364
$329,757 30 Sep 2024
13F
Suncoast Equity Management
13F
Company
0.15%
51,194
$328,665 30 Sep 2024
13F
NORTHERN TRUST CORP
13F
Company
0.14%
48,680
$312,525 30 Sep 2024
13F
Bradley Kroenig
3/4/5
Director
class O/S missing
48,781
$302,442 08 Feb 2024
Hugh Mccoll III
3/4/5
Director
class O/S missing
48,781
$302,442 08 Feb 2024
Talhia Tuck
3/4/5
Director
class O/S missing
48,781
$302,442 08 Feb 2024
STATE STREET CORP
13F
Company
0.1%
36,094
$231,723 30 Sep 2024
13F
Michelle Yanez
3/4/5
Chief Financial Officer
mixed-class rows
224,391
mixed-class rows
$151,224 27 Aug 2024
Beaird Harris Wealth Management, LLC
13F
Company
0.04%
14,623
$93,880 30 Sep 2024
13F
NEW YORK STATE COMMON RETIREMENT FUND
13F
Company
0.03%
11,796
$75,730 30 Sep 2024
13F
MORGAN STANLEY
13F
Company
0.03%
11,454
$73,534 30 Sep 2024
13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
13F
Company
0.03%
10,850
$69,657 30 Sep 2024
13F
LPL Financial LLC
13F
Company
0.03%
10,000
$64,200 30 Sep 2024
13F
BARCLAYS PLC
13F
Company
0.02%
7,018
$45,056 30 Sep 2024
13F
RHUMBLINE ADVISERS
13F
Company
0.01%
4,176
$26,804 30 Sep 2024
13F
BANK OF AMERICA CORP /DE/
13F
Company
0.01%
3,833
$24,608 30 Sep 2024
13F
UBS Group AG
13F
Company
0.01%
3,804
$24,422 30 Sep 2024
13F
CITIGROUP INC
13F
Company
0.01%
3,486
$22,380 30 Sep 2024
13F
JPMORGAN CHASE & CO
13F
Company
0.01%
3,464
$22,239 30 Sep 2024
13F
BNP PARIBAS FINANCIAL MARKETS
13F
Company
0.01%
3,044
$19,542 30 Sep 2024
13F
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
13F
Company
0.01%
2,820
$18,104 30 Sep 2024
13F
Corebridge Financial, Inc.
13F
Company
0.01%
2,572
$16,512 30 Sep 2024
13F
OSAIC HOLDINGS, INC.
13F
Company
0.01%
1,978
$12,698 30 Sep 2024
13F
WELLS FARGO & COMPANY/MN
13F
Company
0.01%
1,799
$11,550 30 Sep 2024
13F
Tower Research Capital LLC (TRC)
13F
Company
0%
1,498
$9,617 30 Sep 2024
13F
ROYAL BANK OF CANADA
13F
Company
0%
1,149
$8,000 30 Sep 2024
13F
Legal & General Group Plc
13F
Company
0%
750
$4,793 30 Sep 2024
13F
Ameritas Investment Partners, Inc.
13F
Company
0%
471
$3,024 30 Sep 2024
13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
13F
Company
0%
349
$2,241 30 Sep 2024
13F
JONES FINANCIAL COMPANIES LLLP
13F
Company
0%
181
$1,234 30 Sep 2024
13F
AMALGAMATED BANK
13F
Company
0%
166
$1,000 30 Sep 2024
13F
FMR LLC
13F
Company
0%
144
$924 30 Sep 2024
13F
EARNED WEALTH ADVISORS, LLC
13F
Company
0%
22
$141 30 Sep 2024
13F
Sterling Capital Management LLC
13F
Company
0%
10
$64 30 Sep 2024
13F
Edward Clouston MacPherson
3/4/5
Director
class O/S missing
25,000
27 Aug 2024
Jerman A. Michael
3/4/5
Director
class O/S missing
25,000
27 Aug 2024
Matthew Paul del Giudice
3/4/5
Director
class O/S missing
25,000
27 Aug 2024
Matthew Pratt Whalen
3/4/5
Director
class O/S missing
25,000
27 Aug 2024

Institutional Holders of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) as of Q4 2024

As of 31 Dec 2024, Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) was held by 37 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,563,053 shares. The largest 10 holders included VANGUARD GROUP INC, BlackRock, Inc., GEODE CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, STATE STREET CORP, Bank of New York Mellon Corp, Suncoast Equity Management, GOLDMAN SACHS GROUP INC, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, and JPMORGAN CHASE & CO. This page lists 37 institutional shareholders reporting positions in this security for the Q4 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q4 2024 vs Q3 2024 Across Filers

Q3 2024 holders
33
Q4 2024 holders
37
Holder diff
4
Investor Q3 2024 Shares Q4 2024 Shares Share Diff Share Chg % Q3 2024 Value $ Q4 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .